During baseline testing of 111 subjects for a one-year, randomized, placebo-controlled, double-blind study, researchers confirmed that although the level of macular pigment, comprised of lutein and zeaxanthin from the diet, varied widely among subjects, it had a significant impact on glare disability, photostress recovery time, and contrast enhancement.
During baseline testing of 111 subjects for a one-year, randomized, placebo-controlled, double-blind study, researchers confirmed that although the level of macular pigment, comprised of lutein and zeaxanthin from the diet, varied widely among subjects, it had a significant impact on glare disability, photostress recovery time, and contrast enhancement.
The baseline testing was done for a trial, now in progress, to determine whether supplementing with Kemin LC’s and DSM’s FloraGLO lutein (10 mg/day) and DSM’s OptiSharp zeaxanthin (2 mg/day) leads to improved visual performance by increasing the level of macular pigment. The test tablets feature DSM’s Actilease technology to maximise the absorption of lutein and zeaxanthin.
The baseline testing results were presented in May at the Association for Research in Vision and Ophthalmology meeting in Fort Lauderdale, FL.
Balchem’s Newest Launch Optifolin+® Brings Innovation to the Folate Market
November 15th 2024Supplement launches featuring 5-MTHF are on the rise with double digit growth. In this episode of Nutritional Outlook’s podcast, we explore Optifolin+®, a new ingredient in the market that offers essential nutrition from prenatal through adulthood. Join us as we uncover the potential impact of the next evolution in folate, setting the stage for a healthier future.
The Nutritional Outlook Podcast Episode 35: Prioritizing Women's Health Research and Innovation
October 28th 2024On this month's episode of the Nutritional Outlook Podcast, Cepham's founder and president, Anand Swaroop, discusses the company's recent announcement to prioritize women's health research and innovation.